In our clinical and animal experiments, we found that an increased number of ILC2s was involved in the IL‐33‐mediated exacerbation of allergen‐induced asthmatic response and aggravated lung tissue inflammation; however, after treatment with anti‐IL‐33 antibody, both the numbers of ILC2s and lung tissue inflammation decreased in EA. Here, IL33 is linked to Esophageal atresia.